Comparative Pharmacology
Head-to-head clinical analysis: EXPAREL versus ROMVIMZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXPAREL versus ROMVIMZA.
EXPAREL vs ROMVIMZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, inhibiting nerve impulse conduction and providing prolonged analgesia.
ROMVIMZA (romipegsim) is a recombinant fusion protein that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates the GLP-1 receptor, increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying, leading to improved glycemic control.
Local infiltration: up to 266 mg (20 mL) as a single dose; interscalene brachial plexus block: up to 133 mg (10 mL); femoral nerve block: up to 133 mg (10 mL). Maximum dose 266 mg. Administer via slow injection with frequent aspiration.
Intravenous administration of 3 mg/kg once every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is 12-48 hours (mean ~24 hours), reflecting prolonged release from the multivesicular liposome depot.
Terminal elimination half-life is 14-18 hours in healthy adults, providing once-daily dosing suitability.
Renal (approximately 96% as metabolites, <10% unchanged). Biliary/fecal excretion is negligible.
Primarily renal (75-80% as unchanged drug) with 20-25% fecal elimination via biliary secretion.
Category C
Category C
Local Anesthetic
Local Anesthetic